Patients & CaregiversHealthcare ProfessionalsWorldwide
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
THE MERCK MANUAL MEDICAL LIBRARY: The Merck Manual of Diagnosis and Therapy
Tips for better results
ABCDEFGHI
JKLMNOPQR
STUVWXYZ

Section

Subject

Topics

Renal Artery Stenosis and Occlusion

Update Me

Renal artery stenosis is a decrease in blood flow through one or both of the main renal arteries or their branches. Renal artery occlusion is a complete blockage of blood flow through one or both of the main renal arteries or its branches. Stenosis and occlusion are usually due to thromboemboli, atherosclerosis, or fibromuscular dysplasia. Symptoms of acute occlusion include steady, aching flank pain, abdominal pain, fever, nausea, vomiting, and hematuria. Acute renal failure may develop. Chronic, progressive stenosis causes refractory hypertension and may lead to chronic kidney disease. Diagnosis is by imaging tests (eg, CT angiography, magnetic resonance angiography). Treatment of acute occlusion is with anticoagulation and sometimes fibrinolytics and surgical or catheter-based embolectomy, or a combination. Treatment of chronic, progressive stenosis includes angioplasty with stenting, surgical bypass, and removal of an infarcted kidney.

Renal hypoperfusion results in hypertension (see Arterial Hypertension: Renovascular Hypertension), renal failure, and, if complete occlusion occurs, renal infarction and necrosis.

Etiology

Occlusion may be acute or chronic. Acute occlusion is usually unilateral. Chronic occlusion may be unilateral or bilateral.

Acute occlusion: The most common cause is thromboembolism. Emboli may originate in the heart (in atrial fibrillation, after MI, or from vegetations due to bacterial endocarditis) or the aorta (as atheroemboli); less often, fat or tumor emboli are the cause. Thrombosis may occur in a renal artery spontaneously or after trauma, surgery, angiography, or angioplasty. Other causes of acute occlusion include dissection or rupture of a renal artery aneurysm.

Rapid, total occlusion of large renal arteries for 30 to 60 min results in infarction. The infarct is typically wedge-shaped, radiating outward from the affected vessel.

Chronic progressive stenosis: About 90% of cases are due to atherosclerosis, which is usually bilateral. Almost 10% of cases are due to fibromuscular dysplasia (FMD), which is commonly unilateral. Less than 1% of cases result from Takayasu's arteritis, Kawasaki disease, neurofibromatosis type 1, aortic wall hematoma, or aortic dissection.

Atherosclerosis develops primarily in patients > 50 (more often men) and usually affects the aortic orifice or proximal segment of the renal artery. Chronic progressive stenosis tends to become clinically evident after about 10 yr of atherosclerosis, causing renal atrophy and chronic kidney disease.

FMD is pathologic thickening of the arterial wall, most often of the distal main renal artery or the intrarenal branches. This disorder develops primarily in younger adults, particularly in women aged 20 to 50. It is more common among first-degree relatives of patients with FMD and among people with the ACE1 gene.

Symptoms and Signs

Manifestations depend on acuteness, extent, whether unilateral or bilateral, and duration of renal hypoperfusion. Stenosis of one renal artery is often asymptomatic for a considerable time.

Acute complete occlusion of one or both renal arteries causes steady and aching flank pain, abdominal pain, fever, nausea, and vomiting. Gross hematuria, oliguria, or anuria may occur; hypertension is rare. After 24 h, symptoms and signs of acute renal failure may develop (see Renal Failure: Symptoms and Signs). If the cause was thromboembolic, features of thromboembolism at other sites (eg, blue toes, livedo reticularis, retinal lesions on funduscopic examination) also may be present.

Chronic progressive stenosis causes hypertension, which may begin at an atypical age (eg, < 30 yr or after age 50 yr) and which may be refractory to control despite use of multiple antihypertensives. Physical examination may detect an abdominal bruit or signs of atherosclerosis. Symptoms and signs of chronic kidney disease (see Renal Failure: Symptoms and Signs) develop slowly.

Diagnosis

  • Clinical suspicion
  • Imaging

Diagnosis is suspected in patients with renal failure and who have

  • Symptoms of acute renal artery occlusion
  • Symptoms or signs of thromboembolism
  • Hypertension that begins before age 30 or is refractory to treatment with > 3 antihypertensive drugs

Blood and urine tests are done to confirm renal failure. Diagnosis is confirmed by imaging tests (see Table 1: Renovascular Disorders: Imaging Tests for Diagnosis of Renal Artery Stenosis or OcclusionTables). Which tests are done depends on the patient's renal function and other characteristics and on test availability.

Some tests (CT angiography, arteriography, digital subtraction angiography) require an IV ionic radiocontrast agent, which may be nephrotoxic; this risk is lower with the nonionic hypo-osmolar or iso-osmolar contrast agents that are now in widespread use (see Principles of Radiologic Imaging: Radiographic Contrast Agents and Contrast Reactions). Magnetic resonance angiography (MRA) requires the use of gadolinium contrast; in patients with severe chronic kidney disease gadolinium contrast carries the risk of nephrogenic systemic fibrosis, a condition that closely resembles scleroderma and that has no satisfactory method of treatment.

When results of other tests are inconclusive or negative but clinical suspicion is strong, arteriography is necessary for definitive diagnosis. Arteriography may also be needed before invasive interventions.

Table 1

Imaging Tests for Diagnosis of Renal Artery Stenosis or Occlusion

Test

Advantages

Disadvantages

CT angiography

Noninvasive

Fast

Generally available

Requires IV iodinated contrast, which may be nephrotoxic

MR angiography

Highly accurate

Noninvasive

Safe in patients with GFR > 60 mL/min and possibly GFR 30—60 mL/min

Requires gadolinium contrast, which increases risk of nephrogenic systemic fibrosis

Doppler ultrasonography

Noninvasive, highly accurate

Provides information about renal function

Operator-dependent, time-consuming, and not always available; limited accuracy in obese patients

Radionuclide renography

Noninvasive; images renal blood flow

More accurate in unilateral than in bilateral stenosis; more accurate when captopril Some Trade Names
CAPOTEN
Click for Drug Monograph
is used; at least 10% false-positive and false-negative rates, even when captopril Some Trade Names
CAPOTEN
Click for Drug Monograph
is used

Usually not used for diagnosis

Arteriography

Diagnostic gold standard

Provides anatomic detail for surgical and invasive radiologic procedures

Invasive

Risk of atheroembolism (due to arterial catheterization) and contrast-induced nephropathy

Digital subtraction angiography

Noninvasive

Uses less iodinated contrast than arteriography

Requires iodinated contrast, but in smaller amounts than arteriography

Carbon dioxide angiography

No need for contrast agent

Relatively unavailable

When a thromboembolic disorder is suspected, ECG (to detect atrial fibrillation) and hypercoagulability studies may be needed to identify treatable embolic sources. Transesophageal echocardiography is done to detect atheromatous lesions in the ascending and thoracic aorta and cardiac sources of thrombi or valvular vegetations.

Blood and urine tests are nondiagnostic but are done to confirm renal failure, indicated by elevated creatinine and BUN and by hyperkalemia. Leukocytosis, gross or microscopic hematuria, and proteinuria may also be present.

Treatment

  • Restoration of vascular patency in acute occlusions and, if patients have refractory hypertension or potential for renal failure, in chronic stenosis

Treatment depends on the cause.

Acute renal artery occlusion: A renal thromboembolic disorder may be treated with a combination of anticoagulation, fibrinolytics, and surgical or catheter-based embolectomy. Treatment within 3 h of symptom onset is likely to improve renal function. However, complete recovery is unusual, and early and late mortality rates are high because of extrarenal embolization or underlying atherosclerotic heart disease.

Patients presenting within 3 h may benefit from fibrinolytic (thrombolytic) therapy (eg, streptokinase Some Trade Names
STREPTASE

, alteplase Some Trade Names
ACTIVASE
Click for Drug Monograph
) given IV or by local intra-arterial infusion (see Coronary Artery Disease: Fibrinolytics). However, such rapid diagnosis and treatment are rare.

All patients with a thromboembolic disorder require anticoagulation with IV heparin Some Trade Names
HEPFLUSH-10
Click for Drug Monograph
, unless contraindicated. Long-term anticoagulation with oral warfarin Some Trade Names
COUMADIN
Click for Drug Monograph
can be initiated simultaneously with heparin Some Trade Names
HEPFLUSH-10
Click for Drug Monograph
if no invasive intervention is planned. Anticoagulation should be continued for at least 6 to 12 mo—indefinitely for patients with a recurrent thromboembolic disorder or a hypercoagulability disorder.

Surgery to restore vascular patency has a higher mortality rate than fibrinolytic therapy and has no advantage in recovery of renal function. However, surgery, particularly if done within the first few hours, is preferred for patients with traumatic renal artery thrombosis. If patients with nontraumatic, severe renal failure do not recover function after 4 to 6 wk of drug therapy, surgical revascularization (embolectomy) can be considered, but it helps only a few.

If the cause is thromboemboli, the source should be identified and treated appropriately (see Peripheral Venous and Lymphatic Disorders: Deep Venous Thrombosis (DVT)).

Chronic progressive renal artery stenosis: Treatment is indicated when >75% arterial diameter is blocked (stenosis) and patients have any of the following:

  • Unilateral stenosis with renal insufficiency
  • Bilateral stenoses
  • Stenosis in a solitary functioning kidney
  • Unilateral or bilateral stenosis associated with hypertension that is refractory to treatment with 3 drugs

Treatment is with percutaneous transluminal angioplasty (PTA) plus stenting, or with surgical bypass of the stenotic segment. Usually, an extensively infarcted kidney must be removed if revascularization is not expected to result in functional recovery. Surgery is usually more effective than PTA for atherosclerotic occlusion; it cures or attenuates hypertension in 60 to 70% of patients. PTA is preferred for FMD; risk is minimal, success rate is high, and restenosis rate is low. If PTA is ineffective, surgical revascularization is needed.

Renovascular hypertension: Treatments are typically ineffective unless vascular patency (see Arterial Hypertension: Treatment) is restored. ACE inhibitors, angiotensin II receptor blockers, or renin inhibitors can be used in unilateral but not in bilateral renal artery stenosis. These drugs can reduce GFR and increase serum BUN and creatinine levels. If GFR decreases enough to increase serum creatinine, Ca channel blockers (eg, amlodipine Some Trade Names
NORVASC
Click for Drug Monograph
, felodipine Some Trade Names
PLENDIL
Click for Drug Monograph
) or vasodilators (eg, hydralazine Some Trade Names
APRESOLINE
Click for Drug Monograph
, minoxidil Some Trade Names
LONITEN
ROGAINE
Click for Drug Monograph
) should be added or substituted (see Arterial Hypertension: Drugs for Hypertension).

Last full review/revision April 2008 by Seyed-Ali Sadjadi, MD

Content last modified April 2008

Back to Top

Previous: Benign Hypertensive Arteriolar Nephrosclerosis

Next: Renal Atheroembolism

Audio
Figures
Photographs
Tables
Videos
Contact UsSite MapPrivacy PolicyTerms of UseCopyright 1995-2007 Merck & Co., Inc.